Biotech

All Articles

FibroGen gives up 75% of US workers as asset fails 2 more trials

.FibroGen is drastically reorganizing its own company, laying off 75% of its united state workers an...

Tracon unwind weeks after injectable PD-L1 inhibitor stop working

.Tracon Pharmaceuticals has chosen to relax functions weeks after an injectable immune checkpoint pr...

Ideaya bags possibility on Biocytogen bispecific ADC in $400M bargain

.Ideaya Biosciences is actually betting $400 million in biobucks that a bispecific antibody-drug con...

Takeda takes $140M reduction on stopped working epilepsy drug, boasts FDA run

.Our company presently recognize that Takeda is actually intending to find a path to the FDA for epi...

VBI Vaccines declare bankruptcy, seeks asset purchase

.Immunology biotech VBI Vaccines is drifting hazardously near the point of no return, along with str...

Celldex anti-cKIT antitoxin decrease colonies in yet another stage 2 research study

.It's difficult to muscle in on an area as very competitive as immunology, but Celldex Therapeutics ...

Boehringer provides to $1.3 B for gate inhibitor biotech

.Boehringer Ingelheim is actually providing to $1.3 billion for Nerio Therapeutics as well as a prec...

Ventyx's last hope for inflammatory med sides in Crohn's breakdown

.Ventyx Biosciences' Crohn's ailment medicine performed not help people obtain remission in a stage ...

Cognition's stage 2 SHINE information tarnish Alzheimer's possibility

.Cognition Therapies' phase 2 sparkle trial has taken a few of the luster off the Alzheimer's ailmen...

BMS centers bispecific months after submitting to work period 3 test

.Bristol Myers Squibb has possessed a whiplash change of mind on its own BCMA bispecific T-cell enga...